{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Maroni R"],"funding":["National Health Service","Cancer Research UK","Medtronic","Yorkshire Cancer Research","NIHR Cambridge Biomedical Research Centre","Medical Research Council","National Institute for Health Research (NIHR)"],"pagination":["e054258"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8990713"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(4)"],"pubmed_abstract":["<h4>Objectives</h4>The BEST3 trial demonstrated the efficacy and safety of the Cytosponge-trefoil factor 3, a cell collection device coupled with the biomarker trefoil factor 3, as a tool for detecting Barrett's oesophagus, a precursor of oesophageal adenocarcinoma (OAC), in primary care. In this nested study, our aim was to understand patient experiences.<h4>Design</h4>Mixed-methods using questionnaires (including Inventory to Assess Patient Satisfaction, Spielberger State-Trait Anxiety Inventory-6 and two-item perceived risk) and interviews.<h4>Outcome measures</h4>Participant satisfaction, anxiety and perceived risk of developing OAC.<h4>Setting</h4>General practices in England.<h4>Participants</h4>Patients with acid reflux enrolled in the intervention arm of the BEST3 trial and attendi"],"journal":["BMJ open"],"pubmed_title":["Patient-reported experiences and views on the Cytosponge test: a mixed-methods analysis from the BEST3 trial."],"pmcid":["PMC8990713"],"funding_grant_id":["C8162/A25356","L389SS","no award/grant number","RG84369","C14478/A21047","C7492/A17219","C8162/A16892","BRC-1215-20014"],"pubmed_authors":["Maroni R","Offman J","Sasieni P","Walter FM","Barnes J","Scheibl F","Rubin G","Smith SG","BEST3 Consortium","Debiram-Beecham I","Waller J","Fitzgerald RC"],"additional_accession":[]},"is_claimable":false,"name":"Patient-reported experiences and views on the Cytosponge test: a mixed-methods analysis from the BEST3 trial.","description":"<h4>Objectives</h4>The BEST3 trial demonstrated the efficacy and safety of the Cytosponge-trefoil factor 3, a cell collection device coupled with the biomarker trefoil factor 3, as a tool for detecting Barrett's oesophagus, a precursor of oesophageal adenocarcinoma (OAC), in primary care. In this nested study, our aim was to understand patient experiences.<h4>Design</h4>Mixed-methods using questionnaires (including Inventory to Assess Patient Satisfaction, Spielberger State-Trait Anxiety Inventory-6 and two-item perceived risk) and interviews.<h4>Outcome measures</h4>Participant satisfaction, anxiety and perceived risk of developing OAC.<h4>Setting</h4>General practices in England.<h4>Participants</h4>Patients with acid reflux enrolled in the intervention arm of the BEST3 trial and attendi","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Apr","modification":"2025-04-05T22:15:38.794Z","creation":"2025-04-05T22:15:38.794Z"},"accession":"S-EPMC8990713","cross_references":{"pubmed":["35393308"],"doi":["10.1136/bmjopen-2021-054258"]}}